Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease

Nature Reviews Nephrology

Volumn 9, Issue 2, 2013, Pages 86-98

  Nagase, Miki ^a   Fujita, Toshiro ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; BUTHIONINE SULFOXIMINE; DEXAMETHASONE; EHT1864; FK 506 BINDING PROTEIN; FOCAL ADHESION KINASE; I KAPPA B; LIM KINASE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NEPHRIN; P21 ACTIVATED KINASE; PROTEIN; PROTEIN CDC42; PYRIMIDINE DERIVATIVE; RAC1 PROTEIN; RAC2 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE RECEPTOR;

APOPTOSIS; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL MOTILITY; CHRONIC KIDNEY DISEASE; DIABETIC CARDIOMYOPATHY; DIASTOLIC HEART FAILURE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FOCAL GLOMERULOSCLEROSIS; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HYPERKALEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; LIGAND BINDING; META ANALYSIS (TOPIC); MORBIDITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEINURIA; QUALITY OF LIFE; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC HEART FAILURE; UPREGULATION;

ANIMALS; HEART DISEASES; HUMANS; KIDNEY DISEASES; MICE; NEUROPEPTIDES; RAC GTP-BINDING PROTEINS; RAC1 GTP-BINDING PROTEIN; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84873106278     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.282     Document Type: Review

References (111)

1. Takai, Y., Sasaki, T. & Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 81, 153-208 (2001).
2. Heasman, S. J. & Ridley, A. J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9, 690-701 (2008).
3. Mundel, P. & Reiser, J. Proteinuria: An enzymatic disease of the podocyte? Kidney Int. 77, 571-580 (2010).
4. Welsh, G. I. & Saleem, M. A. The podocyte cytoskeleton - key to a functioning glomerulus in health and disease. Nat. Rev. Nephrol. 8, 14-21 (2012).
5. Brown, J. H., Del Re, D. P. & Sussman, M. A. The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ. Res. 98, 730-742 (2006).
6. Lezoualc'h, F., Métrich, M., Hmitou, I., Duquesnes, N. & Morel, E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J. Mol. Cell. Cardiol. 44, 623-632 (2008).
7. Briet, M. & Schiffrin, E. L. Aldosterone: Effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6, 261-273 (2010).
8. Bertocchio, J. P., Warnock, D. G. & Jaisser, F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int. 79, 1051-1060 (2011).
9. Williams, G. H. et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 93, 990-996 (2004).
10. Funder, J. W. RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 93, 121-125 (2005).
11. Nagase, M. et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47, 1084-1093 (2006).
12. Shibata, S. et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat. Med. 14, 1370-1376 (2008).
13. Kawarazaki, W. et al. Angiotensin II-and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J. Am. Soc. Nephrol. 23, 997-1007 (2012).
14. Shibata, S. et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J. Clin. Invest. 121, 3233-3243 (2011).
15. Nagase, M. et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 59, 500-506 (2012).
16. Jordan, P., Brazao, R., Boavida, M. G., Gespach, C. & Chastre, E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 18, 6835-6839 (1999).
17. Sugihara, K. et al. Rac1 is required for the formation of three germ layers during gastrulation. Oncogene 17, 3427-3433 (1998).
18. Rossman, K. L., Der, C. J. & Sondek, J. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167-180 (2005).
19. Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and GAPs: Critical elements in the control of small G proteins. Cell 129, 865-877 (2007).
20. Tzima, E. et al. Activation of Rac1 by shear stress in endothelial cells mediates both cytoskeletal reorganization and effects on gene expression. EMBO J. 21, 6791-6800 (2002).
21. Aikawa, R. et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem. Biophys. Res. Commun. 289, 901-907 (2001).
22. Papaharalambus, C. et al. Tumor necrosis factor-a stimulation of Rac1 activity. Role of isoprenylcysteine carboxylmethyltransferase. J. Biol. Chem. 280, 18790-18796 (2005).
23. Kurokawa, K., Itoh, R. E., Yoshizaki, H., Nakamura, Y. O. & Matsuda, M. Coactivation of Rac1 and Cdc42 at lamellipodia and membrane ruffles induced by epidermal growth factor. Mol. Biol. Cell 15, 1003-1010 (2004).
24. Price, L. S., Leng, J., Schwartz, M. A. & Bokoch, G. M. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol. Biol. Cell. 9, 1863-1871 (1998).
25. Lin, C. L. et al. Superoxide destabilization of ß-catenin augments apoptosis of high glucose stressed mesangial cells. Endocrinology 149, 2934-2942 (2008).
26. Shen, E. et al. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58, 2386-2395 (2009).
27. Yi, F., Zhang, A. Y., Janscha, J. L., Li, P. L. & Zou, A. P. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 66, 1977-1987 (2004).
28. Uhlik, M. T. et al. Rac MEKK3 MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat. Cell Biol. 5, 1104-1110 (2003).
29. Friis, M. B. et al. Cell shrinkage as a signal to apoptosis in NIH 3T3 fibroblasts. J. Physiol. 567, 427-443 (2005).
30. Silva, G. B. & Garvin, J. L. Rac1 mediates NaCl-induced superoxide generation in the thick ascending limb. Am. J. Physiol. Renal Physiol. 298, F421-F425 (2010).
31. Liu, R. & Juncos, L. A. GTPase-Rac enhances depolarization-induced superoxide production by the macula densa during tubuloglomerular feedback. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R453-R458 (2010).
32. Schmitz, U. et al. Angiotensin II-induced stimulation of p21-activated kinase and c-Jun NH2-terminal kinase is mediated by Rac1 and Nck. J. Biol. Chem. 276, 22003-22010 (2001).
33. Takemoto, M. et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108, 1429-1437 (2001).
34. Nishida, M. et al. Ga12/13-and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J. Biol. Chem. 280, 18434-18441 (2005).
35. Shibata, S., Nagase, M., Yoshida, S., Kawachi, H. & Fujita, T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49, 355-364 (2007).
36. Iwashima, F. et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149, 1009-1014 (2008).
37. Loirand, G., Scalbert, E., Bril, A. & Pacaud, P. Rho exchange factors in the cardiovascular system. Curr. Opin. Pharmacol. 8, 174-180 (2008).
38. Knaus, U. G., Heyworth, P. G., Evans, T., Curnutte, J. T. & Bokoch, G. M. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 254, 1512-1515 (1991).
39. Abo, A. et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353, 668-670 (1991).
40. Kim, K. S. et al. Protection from reoxygenation injury by inhibition of rac1. J. Clin. Invest. 101, 1821-1826 (1998).
41. Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4, 181-189 (2004).
42. Bustelo, X. R., Sauzeau, V. & Berenjeno, I. M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 29, 356-370 (2007).
43. D'Agati, V. D., Kaskel, F. J. & Falk, R. J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 365, 2398-2411 (2011).
44. Greka, A. & Mundel, P. Cell biology and pathology of podocytes. Annu. Rev. Physiol. 74, 299-323 (2012).
45. Hsu, H. H. et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J. Mol. Med. (Berl.) 86, 1379-1394 (2008).
46. Hoffmann, S., Podlich, D., Hahnel, B., Kriz, W. & Gretz, N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol. 15, 1475-1487 (2004).
47. Tian, D. et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci. Signal. 3, ra77 (2010).
48. Blasi, F. & Carmeliet, P. uPAR: A versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943 (2002).
49. Jiang, M. et al. Ang II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice. J. Clin. Invest. 118, 2733-2746 (2008).
50. Wei, C. et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63 (2008).
51. Akilesh, S. et al. Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J. Clin. Invest. 121, 4127-4137 (2011).
52. Ohta, Y., Hartwig, J. H. & Stossel, T. P. FilGAP, a Rho-and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling. Nat. Cell Biol. 8, 803-814 (2006).
53. Lu, T. C. et al. HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J. Biol. Chem. 283, 8173-8182 (2008).
54. Lu, H. et al. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 114, 2271-2279 (2006).
55. Maack, C. et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108, 1567-1574 (2003).
56. Adam, O. et al. Role of Rac1 GTPase activation in atrial fibrillation. J. Am. Coll. Cardiol. 50, 359-367 (2007).
57. Morel, E. et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ. Res. 97, 1296-1304 (2005).
58. Liao, J. K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288 (2002).
59. Kawamura, S., Miyamoto, S. & Brown, J. H. Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae: Cytoskeletal regulation of ERK translocation. J. Biol. Chem. 278, 31111-31117 (2003).
60. Pracyk, J. B. et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J. Clin. Invest. 102, 929-937 (1998).
61. Gronemeyer, H., Gustafsson, J. A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964 (2004).
62. Qin, W. et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 93, 69-76 (2003).
63. Garnier, A. et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819-1825 (2004).
64. Ouvrard-Pascaud, A. et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025-3033 (2005).
65. Brilla, C. G. & Weber, K. T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901 (1992).
66. Fraccarollo, D. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408 (2011).
67. Lother, A. et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57, 746-754 (2011).
68. Beygui, F. et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114, 2604-2610 (2006).
69. Guder, G. et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115, 1754-1761 (2007).
70. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
71. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
72. Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
73. McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012).
74. Edelmann, F. et al. Rationale and design of the 'Aldosterone Receptor Blockade in Diastolic Heart Failure' trial: A double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 12, 874-882 (2010).
75. Desai, A. S. et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am. Heart J. 162, 966-972 e910 (2011).
76. He, B. J. et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610-1618 (2011).
77. Rickard, A. J. et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54, 537-543 (2009).
78. Togawa, A. et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIa. Oncogene 18, 5373-5380 (1999).
79. Su, L. F., Knoblauch, R. & Garabedian, M. J. Rho GTPases as modulators of the estrogen receptor transcriptional response. J. Biol. Chem. 276, 3231-3237 (2001).
80. Cai, D. et al. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 63, 6802-6808 (2003).
81. Wang, R. A., Mazumdar, A., Vadlamudi, R. K. & Kumar, R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-a and promotes hyperplasia in mammary epithelium. EMBO J. 21, 5437-5447 (2002).
82. Lyons, L. S. et al. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol. Endocrinol. 22, 597-608 (2008).
83. Kino, T. et al. Rho family guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system. J. Biol. Chem. 281, 9118-9126 (2006).
84. Nagase, M., Matsui, H., Shibata, S., Gotoda, T. & Fujita, T. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50, 877-883 (2007).
85. Engeli, S. et al. Weight loss and the reninYangiotensinYaldosterone system. Hypertension 45, 356-362 (2005).
86. Matsui, H. et al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 52, 287-294 (2008).
87. Giordano, F. J. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115, 500-508 (2005).
88. Matsui, Y. et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43, 1195-1201 (2004).
89. Fiebeler, A. et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-?B activation in angiotensin II-induced cardiac injury. Hypertension 37, 787-793 (2001).
90. Wehling, M. Specific, nongenomic actions of steroid hormones. Annu. Rev. Physiol. 59, 365-393 (1997).
91. Frost, J. A. et al. Stimulation of NF?B activity by multiple signaling pathways requires PAK1. J. Biol. Chem. 275, 19693-19699 (2000).
92. Simon, A R. et al. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290, 144-147 (2000).
93. Kawashima, T. et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J. Cell Biol. 175, 937-946 (2006).
94. Wu, X. et al. Rac1 activation controls nuclear localization of ß-catenin during canonical Wnt signaling. Cell 133, 340-353 (2008).
95. Galigniana, M. D., Erlejman, A. G., Monte, M., Gomez-Sanchez, C. & Piwien-Pilipuk, G. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol. Cell. Biol. 30, 1285-1298 (2010).
96. Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T. & Cox, M. B. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol. Metab. 22, 481-490 (2011).
97. Kim, J. H. et al. Podocyte injury induces nuclear translocation of WTIP via microtubule-dependent transport. J. Biol. Chem. 285, 9995-10004 (2010).
98. Guess, A. et al. Dose-and time-dependent glucocorticoid receptor signaling in podocytes. Am. J. Physiol. Renal Physiol. 299, F845-F853 (2010).
99. Best, A., Ahmed, S., Kozma, R. & Lim, L. The Ras-related GTPase Rac1 binds tubulin. J. Biol. Chem. 271, 3756-3762 (1996).
100. Buscemi, N. et al. Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 289, H2325-H2333 (2005).
101. Weigel, N. L. & Moore, N. L. Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl. Recept. Signal. 5, e005 (2007).
102. McKenna, N. J. & O'Malley, B. W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474 (2002).
103. Denner, L. A., Weigel, N. L., Maxwell, B. L., Schrader, W. T. & O'Malley, B. W. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250, 1740-1743 (1990).
104. Massaad, C., Houard, N., Lombes, M. & Barouki, R. Modulation of human mineralocorticoid receptor function by protein kinase A. Mol. Endocrinol. 13, 57-65 (1999).
105. Le Moellic, C. et al. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCa activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J. Am. Soc. Nephrol. 15, 1145-1160 (2004).
106. Yokota, K. et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J. Biol. Chem. 282, 1998-2010 (2007).
107. Murai-Takeda, A. et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J. Biol. Chem. 285, 8084-8093 (2010).
108. Viengchareun, S. et al. The mineralocorticoid receptor: Insights into its molecular and (patho)physiological biology. Nucl. Recept. Signal. 5, e012 (2007).
109. Yang, J. & Fuller, P. J. Interactions of the mineralocorticoid receptor-within and without. Mol. Cell. Endocrinol. 350, 196-205 (2012).
110. Miralles, F. & Visa, N. Actin in transcription and transcription regulation. Curr. Opin. Cell. Biol. 18, 261-266 (2006).
111. Ando, K. et al. Rationale and design of the Eplerenone Combination Versus Conventional Agents to Lower Blood Pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: A double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens. Res. 33, 616-621 (2010).